Edesa Biotech Inc. (NASDAQ: EDSA) announced it entered into a securities purchase agreement for a private investment in public equity financing expected to generate gross proceeds of approximately $3.5 million before deducting offering expenses.

The clinical-stage biopharmaceutical company sold 729,241 common shares in the private placement. Investors paid $4.69 per share, while the company's chief executive officer paid $5.21 per share. The financing was completed without an agent, underwriter, broker or dealer.

Participants in the financing include Edesa's CEO and healthcare-focused investors. The transaction is expected to close on or about June 15, 2026, subject to customary closing conditions.

The company stated it expects to use net proceeds to fund continued advancement of its vitiligo program and drug candidate paridiprubart, as well as for working capital and general corporate purposes.

The securities were offered under Section 4(a)(2) of the Securities Act of 1933 and Regulation D, and have not been registered under the Act. Edesa agreed to file a registration statement with the Securities and Exchange Commission for resale of the common shares within 45 days of closing.

Edesa develops treatments for inflammatory and immune-related diseases, with a clinical pipeline focused on medical dermatology and respiratory conditions. The company's medical dermatology assets include EB06 for vitiligo and EB01 for allergic contact dermatitis. Its respiratory program centers on paridiprubart for acute respiratory distress syndrome.